Search Result

Results for "

kidney disease

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (2) Angiotensin Receptor (4) Angiotensin-converting Enzyme (ACE) (3) Antibiotic (1) Apoptosis (5) Autophagy (3) Cannabinoid Receptor (1) CD28 (1) CDK (5) CFTR (1) COX (1) Cytochrome P450 (1) Dynamin (1) EGFR (1) Endogenous Metabolite (16) Epigenetic Reader Domain (2) Ferroptosis (1) FXR (2) GABA Receptor (2) Glucosylceramide Synthase (GCS) (3) GSK-3 (1) HIF/HIF Prolyl-Hydroxylase (5) Histone Methyltransferase (2) HIV Integrase (1) Interleukin Related (1) Isotope-Labeled Compounds (1) Keap1-Nrf2 (2) Ketohexokinase (1) Lipoxygenase (1) MicroRNA (1) Mineralocorticoid Receptor (4) Mitophagy (1) Monoamine Oxidase (2) Necroptosis (1) Neurotensin Receptor (1) NF-κB (5) NKCC (2) NO Synthase (1) Opioid Receptor (2) PDGFR (1) Phospholipase (1) PINK1/Parkin (1) Potassium Channel (1) Prostaglandin Receptor (2) Proton Pump (1) Ras (1) Reactive Oxygen Species (1) RET (1) RIP kinase (1) Sirtuin (3) STAT (4) TGF-beta/Smad (1) Toll-like Receptor (TLR) (1) TRP Channel (5) Vasopressin Receptor (1) VEGFR (1) Xanthine Oxidase (1)
By Research Areas:	Cancer (14) Cardiovascular Disease (24) Endocrinology (14) Infection (3) Inflammation/Immunology (25) Metabolic Disease (40) Neurological Disease (9)

By Targets:

Adenosine Receptor (2)

Angiotensin Receptor (4)

Angiotensin-converting Enzyme (ACE) (3)

Antibiotic (1)

Apoptosis (5)

Autophagy (3)

Cannabinoid Receptor (1)

CD28 (1)

CDK (5)

CFTR (1)

COX (1)

Cytochrome P450 (1)

Dynamin (1)

EGFR (1)

Endogenous Metabolite (16)

Epigenetic Reader Domain (2)

Ferroptosis (1)

FXR (2)

GABA Receptor (2)

Glucosylceramide Synthase (GCS) (3)

GSK-3 (1)

HIF/HIF Prolyl-Hydroxylase (5)

Histone Methyltransferase (2)

HIV Integrase (1)

Interleukin Related (1)

Isotope-Labeled Compounds (1)

Keap1-Nrf2 (2)

Ketohexokinase (1)

Lipoxygenase (1)

MicroRNA (1)

Mineralocorticoid Receptor (4)

Mitophagy (1)

Monoamine Oxidase (2)

Necroptosis (1)

Neurotensin Receptor (1)

NF-κB (5)

NKCC (2)

NO Synthase (1)

Opioid Receptor (2)

PDGFR (1)

Phospholipase (1)

PINK1/Parkin (1)

Potassium Channel (1)

Prostaglandin Receptor (2)

Proton Pump (1)

Ras (1)

Reactive Oxygen Species (1)

RET (1)

RIP kinase (1)

Sirtuin (3)

STAT (4)

TGF-beta/Smad (1)

Toll-like Receptor (TLR) (1)

TRP Channel (5)

Vasopressin Receptor (1)

VEGFR (1)

Xanthine Oxidase (1)

By Research Areas:

Cancer (14)

Cardiovascular Disease (24)

Endocrinology (14)

Infection (3)

Inflammation/Immunology (25)

Metabolic Disease (40)

Neurological Disease (9)

101

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17623C

(R)-Tegoprazan (R)-CJ-12420; (R)-RQ-00000004	Proton Pump	Metabolic Disease
(R)-Tegoprazan (example 3), a benzimidazole derivative, is a potent kidney H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 98 nM of canine kidney Na ⁺/K ⁺-ATPase. (R)-Tegoprazan has the potential for gastrointestinal diseases research .

HY-P5314

OK2	EGFR STAT	Others
OK2, a specific inhibitor of the CCN2/EGFR interaction, efficiently blocks CCN2/EGFR interaction through binding to the CT domain of CCN2. OK2 can be used for kidney fibrosis and chronic kidney disease research .

HY-13995A

Sevelamer hydrochloride 1 Publications Verification	FXR Autophagy	Others
Sevelamer hydrochloride is an orally active and phosphate binding agent used for research of hyperphosphatemia with chronic kidney disease. Sevelamer hydrochloride consists of polyallylamine that is crosslinked with epichlorohydrin .

HY-153092

Avenciguat BI-685509	Others	Cardiovascular Disease Metabolic Disease
Avenciguat (BI-685509) is a potent and orally active sGC activator. Avenciguat restores cyclic guanosine monophosphate (cGMP) and improves functionality of nitric oxide (NO) pathways. Avenciguat can be used in research of chronic kidney disease (CKD) and diabetic kidney disease (DKD) .

HY-139725

CDK5-IN-1

CDK Metabolic Disease

CDK5-IN-1, a potent CDK5 inhibitor, is against CDK5 activity less than 10 nM. CDK5-IN-1 is used for kidney diseases research .

CDK5-IN-1	CDK	Metabolic Disease
CDK5-IN-1, a potent CDK5 inhibitor, is against CDK5 activity less than 10 nM. CDK5-IN-1 is used for kidney diseases research .

HY-14179

PPQ-102 3 Publications Verification CFTR Inhibitor	CFTR	Others
PPQ-102 (CFTR Inhibitor) is a reversible CFTR inhibitor that completely inhibits CFTR chloride currents (IC₅₀ ~90 nM). PPQ-102 is not affected by membrane potential-dependent cell allocation or blocking efficiency (uncharged at physiological pH) and effectively prevents cyst enlargement in polycystic kidney disease .

HY-120441

CAY10590 GK115	Phospholipase Prostaglandin Receptor	Inflammation/Immunology
CAY10590 (GK115) is an inhibitor of secreted phospholipase A₂ (sPLA₂) and can be used for the research of chronic inflammatory kidney diseases .

HY-W416250

p-Cresol glucuronide	Others	Cardiovascular Disease
p-Cresol glucuronide, a metabolite of p-cresol, is a prototype protein-bound uremic toxin. p-Cresol glucuronide is associated with chronic kidney disease (CKD) .

HY-128442

Phenyl sulfate Phenyl hydrogen sulfate	Endogenous Metabolite	Metabolic Disease
Phenyl sulfate is an orally active gut microbiota-derived metabolite. Phenyl sulfate induces albuminuria and podocyte damage in experimental models of diabetes. Phenyl sulfate can be used as a disease marker and future therapeutic target in diabetic kidney disease .

HY-101277

Vadadustat 4 Publications Verification PG-1016548; AKB-6548	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor . Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo .

HY-146155

TRPC4/5-IN-1	TRP Channel	Metabolic Disease Inflammation/Immunology
TRPC4/5-IN-1 is a potent TRP channel 4/5 (TRPC4/5) inhibitor with IC₅₀s of 2.06 μM and 0.54 μM, respectively. TRPC4/5-IN-1 can be used for proteinuric kidney diseases and skin inflammatory diseases research .

HY-111547

M1001	HIF/HIF Prolyl-Hydroxylase	Cancer
M1001 is a weak hypoxia-inducible factor-2α (HIF-2α) agonist. M1001 can bind to the HIF-2α PAS-B domain, with a K_d of 667 nM. M1001 can be used in chronic kidney disease research .

HY-146272

Vasopressin V2 receptor antagonist 1	Vasopressin Receptor	Metabolic Disease
Vasopressin V2 receptor antagonist 1 (Compound 4g) is a vasopressin V₂ receptor (V₂R) antagonist with a K_i of 3.8 nM. Vasopressin V2 receptor antagonist 1 can be used for autosomal dominant polycystic kidney disease (ADPKD) research .

HY-144429

TRPC5-IN-4	TRP Channel	Metabolic Disease
TRPC5-IN-4 is potent and safe TRPC inhibitor with IC₅₀ value of 14.07 nM and 65 nM for TRPC5 and TRPC4, respectively. TRPC5-IN-4 shows no damage on the cellular component of liver and kidney. TRPC5-IN-4 can be used for the research of chronic kidney disease (CKD) .

HY-N1428C

Ferric citrate 1 Publications Verification Iron(III) citrate; Zerenex	Reactive Oxygen Species Antibiotic	Metabolic Disease
Ferric citrate (Iron(III) citrate), an orally active iron supplement, is an efficacious phosphate binder. Ferric citratee can be used for iron deficiency anemia and chronic kidney disease (CKD) research .

HY-146478

A1/A3 AR antagonist 1	Adenosine Receptor	Neurological Disease Inflammation/Immunology
A1/A3 AR antagonist 1 (compound 10) is a potent adenosine 1 (A1) and adenosine 3 (A3) receptor dual antagonist with K_is of 36.7 nM, 25.4 nM and 1.47 nM for human A1, human A3 and rat A1, respectively. A1/A3 AR antagonist 1 can be used for researching kidney failure, inflammatory pulmonary diseases, and Alzheimer’s disease .

HY-17609

Difelikefalin CR-845; FE-202845	Opioid Receptor	Neurological Disease
Difelikefalin (CR-845; FE-202845) is a peripherally restricted and selective agonist of kappa opioid receptor (KOR). Difelikefalin produces anti-inflammatory effects and has the potential in modulating pruritus in conditions such as chronic kidney disease .

HY-161026

JM-9	Toll-like Receptor (TLR)	Inflammation/Immunology
JM-9 is a inhibitor of MD2. JM-9 suppresses high glucose and palmitic acid -induced inflammation in MPMs. JM-9 improves diabetic kidney disease by inhibiting MD2-mediated inflammation .

HY-122052

UK‑396082	Others	Metabolic Disease
UK‑396082 is a potent thrombin activated fibrinolytic inhibitor (TAFI) inhibitor. UK‑396082 increases plasmin activity and induces a parallel decrease in ECM levels. UK‑396082 can be used in research of chronic kidney disease (CKD) .

HY-120274

Balcinrenone AZD9977	Mineralocorticoid Receptor	Cardiovascular Disease Metabolic Disease
Balcinrenone (AZD9977) is a potent, selective, and orally active mineralocorticoid receptor (MR) modulator. Balcinrenone is used for heart failure, and chronic kidney disease research .

HY-145150

TRPC5-IN-1	TRP Channel	Metabolic Disease
TRPC5-IN-1 (Compound 6j) is a selective TRPC5 inhibitor with 50.5 % Inhibition for TRPC5 at 3 μM. TRPC5-IN-1 can be used for the research of chronic kidney disease (CKD) .

HY-150076

BLU2864	Others	Metabolic Disease Cancer
BLU2864 is an orally active, highly selective, ATP-competitive PRKACA inhibitor (IC₅₀=0.3 nM). BLU2864 shows anti-tumor activity. BLU2864 can be used in cancer and polycystic kidney disease research .

HY-119572

Sodium zirconium cyclosilicate	Others	Inflammation/Immunology
Sodium zirconium cyclosilicate is an orally administered, non-absorbed, novel, inorganic microporous zirconium silicate compound, is a highly selective cation exchanger that selectively removes excess K ⁺ in vivo. Sodium zirconium cyclosilicate can be used in research of chronic kidney disease (CKD) .

HY-139290

RGLS4326 RG4326	MicroRNA	Metabolic Disease Cancer
RGLS4326 (RG4326) is a first-in-class, short oligonucleotide inhibitor of microRNA-17 (miR-17). RGLS4326 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD). RGLS4326 inhibits miR-17 function in HeLa cells with an EC₅₀ value of 28.3 nM .

HY-111372

Finerenone 2 Publications Verification BAY 94-8862	Mineralocorticoid Receptor	Cardiovascular Disease
Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-143721

SSAO inhibitor-2	Monoamine Oxidase	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
SSAO inhibitor-2 (Compound 1) is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor with IC₅₀s of <10 nM, and 10-100 μM for human SSAO and MAO-A, respectively. SSAO inhibitor-3 can be used for the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc .

HY-143723

SSAO inhibitor-3	Monoamine Oxidase	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
SSAO inhibitor-3 (Compound 2) is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor with IC₅₀s of <10 nM, and 0.1-10 μM for human SSAO and AOC1, respectively. SSAO inhibitor-3 can be used for the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc .

HY-B0130A

Perindopril erbumine 4 Publications Verification Perindopril tert-butylamine salt; S-9490 erbumine	Sirtuin NF-κB STAT Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease Cancer
Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NF-κB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure .

HY-151878

CDK7-IN-20	CDK GSK-3	Metabolic Disease
CDK7-IN-20 is a potent, selective and irreversible CDK7 (CDK) inhibitor with an IC₅₀ value of 4 nM. CDK7-IN-20 displays >206-fold selectivity for CDK7 over CDK1, CDK2, CDK3, CDK5, CDK6, CDK9 and CDK12 . CDK7-IN-20 has the potential for autosomal dominant polycystic kidney disease (ADPKD) research .

HY-123572

Bis-T-23 AG1717	Dynamin HIV Integrase	Infection Metabolic Disease Inflammation/Immunology
Bis-T-23 (AG1717), tyrphostin derivative, is an HIV-I integrase inhibitor. Bis-T-23 can promote actin-dependent dynamin oligomerization. Bis-T-23 can be used for the research of HIV and chronic kidney diseases (CKD) .

HY-149987

LY3522348 KHK-IN-3	Ketohexokinase	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
KHK-IN-3 (Example 1) is a ketohexokinase (KHK) inhibitor. KHK-IN-3 can be used in the study of kidney disease, nonalcoholic steatohepatitis (NASH), diabetes and heart failure. KHK is a rate-limiting enzyme and fructokinase involved in fructose metabolism. KHK catalyzes the phosphorylation of fructose to fructose-1-phosphate (FIP) at the expense of ATP. The lack of feedback inhibition of fructose metabolism triggers the accumulation of downstream intermediates such as lipogenesis, gluconeogenesis, and oxidative phosphorylation .

HY-13995B

Sevelamer carbonate 1 Publications Verification	Others	Metabolic Disease
Sevelamer carbonate is an orally active and non-calcium-based phosphate binding agent and used for the hyperphosphatemia of chronic kidney disease (CKD)research. Sevelamer carbonate effectively lowers serum phosphorus levels hile having minimal effect on serum calcium or serum chloride levels in vivo. Sevelamer carbonate is considered as an improved, buffered form of sevelamer (HY-13995) .

HY-160636

BRD4 Inhibitor-32

Epigenetic Reader Domain Others

BRD4 Inhibitor-32 (example 15) is a BRD4 inhibitor that can be used in acute kidney disease and chronic kidney disease research .
HY-160660

BRD4 Inhibitor-33

Epigenetic Reader Domain Others

BRD4 Inhibitor-33 (example 13) is a BRD4 inhibitor that can be used in acute kidney disease and chronic kidney disease research .

BRD4 Inhibitor-32	Epigenetic Reader Domain	Others
BRD4 Inhibitor-32 (example 15) is a BRD4 inhibitor that can be used in acute kidney disease and chronic kidney disease research .

BRD4 Inhibitor-33	Epigenetic Reader Domain	Others
BRD4 Inhibitor-33 (example 13) is a BRD4 inhibitor that can be used in acute kidney disease and chronic kidney disease research .

HY-B0130

Perindopril 4 Publications Verification S-9490	Angiotensin-converting Enzyme (ACE) NF-κB STAT Sirtuin	Cardiovascular Disease Neurological Disease Cancer
Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NFκB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure .

HY-153911

H2-Gamendazole	Others	Endocrinology
H2-Gamendazole is a derivative of Lonidamine that reduces cyst formation in polycystic kidney disease and is used in autosomal dominant polycystic kidney disease research .

HY-101410

SDMA Symmetric dimethylarginine; NG,NG'-Dimethyl-L-arginine	Endogenous Metabolite	Inflammation/Immunology
SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity. SDMA, a novel kidney biomarker, permits earlier diagnosis of kidney disease than traditional creatinine testing.

HY-18627A

PFI-2 hydrochloride 5+ Cited Publications (R)-PFI-2 hydrochloride	Histone Methyltransferase	Infection Inflammation/Immunology Cancer
PFI-2 ((R)-PFI-2 hydrochloride) hydrochloride is a potent and selective SET domain containing lysine methyltransferase 7 (SETD7) inhibitor. (R)-PFI-2 shows high inhibiting activity with IC₅₀ value of 2.0 nM and (S)-PFI-2 shows inhibiting activity with IC₅₀ value of 1.0 μM. PFI-2 hydrochloride can be used for the research of chronic kidney disease and inflammation response in the development of renal fibrosis .

HY-18627

PFI-2 (R)-PFI-2	Histone Methyltransferase	Infection Inflammation/Immunology Cancer
PFI-2 ((R)-PFI-2 hydrochloride) hydrochloride is a potent and selective SET domain containing lysine methyltransferase 7 (SETD7) inhibitor. (R)-PFI-2 shows high inhibiting activity with IC₅₀ value of 2.0 nM and (S)-PFI-2 shows inhibiting activity with IC₅₀ value of 1.0 μM. PFI-2 hydrochloride can be used for the research of chronic kidney disease and inflammation response in the development of renal fibrosis .

HY-B0202

Irbesartan 5 Publications Verification SR-47436; BMS-186295	Angiotensin Receptor Apoptosis	Cardiovascular Disease Endocrinology
Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease .

HY-B0202A

Irbesartan hydrochloride SR-47436 hydrochloride; BMS-186295 hydrochloride	Angiotensin Receptor Apoptosis	Neurological Disease Metabolic Disease
Irbesartan (SR-47436) hydrochloride is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan hydrochloride can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan hydrochloride can be used for the research of high blood pressure, heart failure, and diabetic kidney disease .

HY-13995

Sevelamer	FXR Autophagy	Endocrinology
Sevelamer is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease; consists of polyallylamine that is crosslinked with epichlorohydrin.

HY-132827

Ocedurenone KBP-5074	Mineralocorticoid Receptor	Endocrinology
Ocedurenone is a corticosteroid receptor antagonist. Ocedurenone can be used for the research of kidney disease (WO2018054357, compound I) .

HY-16743

Ibiglustat 2 Publications Verification Venglustat; SAR402671; GZ402671	Glucosylceramide Synthase (GCS)	Metabolic Disease
Ibiglustat (Venglustat) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .

HY-16743B

Ibiglustat succinate 2 Publications Verification Venglustat succinate; SAR402671 succinate; GZ402671 succinate	Glucosylceramide Synthase (GCS)	Neurological Disease
Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat succinate can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .

HY-111431

p-Cresyl sulfate 1 Publications Verification p-Tolyl sulfate	Endogenous Metabolite	Metabolic Disease
p-Cresyl Sulfate, a major uremic toxin derived from the metabolites of tyrosine and phenylalanine through liver, existed in the blood of patients with chronic kidney disease (CKD).

HY-16743A

Ibiglustat (L-Malic acid) 2 Publications Verification Venglustat (L-Malic acid); SAR402671 (L-Malic acid); GZ402671 (L-Malic acid)	Glucosylceramide Synthase (GCS)	Metabolic Disease
Ibiglustat (Venglustat) L-Malic acid is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat L-Malic acid can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .

HY-17608

Daprodustat 5+ Cited Publications GSK1278863	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Daprodustat (GSK1278863) is an orally active hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor being developed for the treatment of anemia associated with chronic kidney disease.

HY-107929

Calcium polystyrene sulfonate Poly(styrenesulfonic acid) calcium salt	Others	Cardiovascular Disease
Calcium polystyrene sulfonate is an ion-exchange resin used for reducing blood levels of potassium. Calcium polystyrene sulfonate is used to treat hyperkalemia in patients with chronic kidney disease (CKD).

HY-163148

PHD-IN-3	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
PHD-IN-3 (Compound 15) is an orally active PHD inhibitor. PHD-IN-3 can be used in the study of anemia associated with chronic kidney disease .

Cat. No.	Product Name

HY-L018

TGF-beta/Smad Compound Library

223 compounds

The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc.

MCE designs a unique collection of 223 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.

HY-L040

Anti-diabetic Compound Library

740 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 740 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-128442

Phenyl sulfate Phenyl hydrogen sulfate	Structural Classification Natural Products Human Gut Microbiota Metabolites Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Phenyl sulfate is an orally active gut microbiota-derived metabolite. Phenyl sulfate induces albuminuria and podocyte damage in experimental models of diabetes. Phenyl sulfate can be used as a disease marker and future therapeutic target in diabetic kidney disease .

HY-B0130

Perindopril 4 Publications Verification S-9490	Cardiovascular Disease Classification of Application Fields Disease Research Fields	Angiotensin-converting Enzyme (ACE) NF-κB STAT Sirtuin
Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NFκB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure .

HY-101410

SDMA Symmetric dimethylarginine; NG,NG'-Dimethyl-L-arginine	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Other disease Ketones, Aldehydes, Acids Source classification Disease markers Endogenous metabolite Inflammation/Immunology Disease Research Fields	Endogenous Metabolite
SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity. SDMA, a novel kidney biomarker, permits earlier diagnosis of kidney disease than traditional creatinine testing.

HY-111431

p-Cresyl sulfate 1 Publications Verification p-Tolyl sulfate	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
p-Cresyl Sulfate, a major uremic toxin derived from the metabolites of tyrosine and phenylalanine through liver, existed in the blood of patients with chronic kidney disease (CKD).

HY-18260

Bisphenol A 5+ Cited Publications	Classification of Application Fields Source classification Phenols Polyphenols Endogenous metabolite Disease Research Fields Endocrinology	Endogenous Metabolite
Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders .

HY-N2608

7-O-Ethylmorroniside	Structural Classification Iridoids Classification of Application Fields Cornaceae Cornus officinalis Sieb. et Zucc. Terpenoids Source classification Metabolic Disease Plants Disease Research Fields	Others
7-O-Ethylmorroniside is a iridoid glucoside from the fruit of Cornus officinalis which is a traditional medicine in China and used for the reserch of kidney diseases, including diabetic nephropathy .

HY-18260R

Bisphenol A (Standard)	Structural Classification Classification of Application Fields Source classification Phenols Endogenous metabolite Disease Research Fields Endocrinology	Endogenous Metabolite
Bisphenol A (Standard) is the analytical standard of Bisphenol A. This product is intended for research and analytical applications. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders .

HY-113089

Epsilon-(gamma-glutamyl)-lysine H-Glu(H-Lys-OH)-OH; γ-Glu-ε-Lys	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Epsilon-(gamma-glutamyl)-lysine is an N(6)-acyl-L-lysine derivative. The enzyme tissue transglutaminase (tTg) helps the formation of epsilon-(gamma-glutamyl)lysine bonds between ECM components in some disease, such as non-diabetic kidney, glaucoma filtration .

HY-W013215

Adrenic acid cis-7,10,13,16-Docosatetraenoic acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Endogenous Metabolite
Adrenic Acid (cis-7,10,13,16-Docosatetraenoic acid) is a naturally polyunsaturated fatty acid in the adrenal gland, brain, kidney, and vasculature. Adrenic Acid can regulate the vascular tone in arteries of the adrenal cortex. Adrenic Acid also is an inflammation enhancer in non-alcoholic fatty liver disease .

HY-113089A

Epsilon-(gamma-glutamyl)-lysine TFA H-Glu(H-Lys-OH)-OH TFA; γ-Glu-ε-Lys TFA	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Epsilon-(gamma-glutamyl)-lysine (H-Glu(H-Lys-OH)-OH) TFA is an N(6)-acyl-L-lysine derivative. The enzyme tissue transglutaminase (tTg) helps the formation of epsilon-(gamma-glutamyl)lysine bonds between ECM components in some disease, such as non-diabetic kidney, glaucoma filtration .

HY-N0164

Matrine Maximum Cited Publications 12 Publications Verification Matridin-15-one; Vegard; α-Matrine	Structural Classification Classification of Application Fields Source classification Sophora flavescens Aiton Plants Biological Pesticide Research Agricultural Research Alkaloids Piperidine Alkaloids Leguminosae Inflammation/Immunology Disease Research Fields Cancer	PINK1/Parkin Opioid Receptor Autophagy Mitophagy Ferroptosis Apoptosis
Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI) .

HY-135772

12-Ketodeoxycholic acid 12-Ketolithocholic acid	Structural Classification Microorganisms Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
12-Ketodeoxycholic acid (12-Ketolithocholic acid) is a bile acid, metabolite from kidney. 12-Ketodeoxycholic acid can be a detectable marker for evidence of kidney injury

HY-W674241A

4-Ethylphenyl sulfate sodium	Structural Classification Natural Products Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
4-Ethylphenyl sulfate sodium is a gut microbial metabolite. 4-Ethylphenyl sulfate sodium is also a protein-bound uremic toxin, a xenobiotic substrate, and causes endothelial dysfunction .

Cat. No.	Product Name	Chemical Structure

HY-18260S1

Bisphenol A-d6

Bisphenol A-d₆ is the deuterium labeled Bisphenol A. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[1][2][3].

HY-18260S

Bisphenol A-d16

Bisphenol A-d₁₆ is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3].

HY-18260S4

Bisphenol A-d4

Bisphenol A-d₄ is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3].

HY-18260S6

Bisphenol A-d14

Bisphenol A-d₁₄ is a deuterium labeled Bisphenol A (HY-18260). Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders .

HY-18260S3

Bisphenol A-d8

Bisphenol A-d₈ is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3][4].

HY-18260S5

Bisphenol A-d4-1

Bisphenol A-d₄-1 is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3].

HY-B0202S2

Irbesartan-d6-1
Irbesartan-d₆-1 is the deuterium labeled Irbesartan[1]. Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease[2].

HY-111372S

Finerenone-d3

Finerenone-d3 is the deuterium labeled finerenone (HY-111372). Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks